Clinical trials: Intestinal Neoplasm, open to volunteers
Rectal Cancer
A Study on the Accurate Evaluation of Pseudoprogression of Rectal Cancer Immunotherapy Based on Multitemporal and Multiparameter MRI
This project aims to use multi-temporal, multi-parameter MRI features, blood biomarkers, and clinical indicators to accurately assess pseudoprogression following immunotherapy in rectal cancer.
- Trial name
- NCT07381322
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Peiyi Xie
Colorectal Neoplasms, RAS
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Colorectal cancer is a malignant tumor ranking among the top four in incidence and the top three in causes of death globally . Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies is currently the standard…
- Conditions
- Colorectal Neoplasms, RAS, BRAF, Cetuximabβ
- Trial name
- concept (NCT07257653)
- Testing
- Cetuximab β；Fruquintinib；, Cetuximab β；Fruquintinib；anti-PD1 antibody；, Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang University
Breast Carcinoma, Cervical Carcinoma
The Ohio State University (OSU) SCREEN Community Program
This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC)…
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
- Trial name
- NCT06666192
- Testing
- Cancer Screening, Discussion, Educational Activity
- Where
- United States
- Volunteers
- 2,067 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Appendix Cancer, Pseudomyxoma Peritonei
The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
ACPMP's first-ever patient-powered global patient registry/natural history study collects patient and caregiver information and data to fuel clinical trials and drive breakthroughs for appendix cancer and PMP.
- Trial name
- NCT07769346
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Appendix Cancer Pseudomyxoma Peritonei Research Foundation
Depression, Cancer
Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.
- Conditions
- Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT06811454
- Testing
- MINDSET, Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Depression - Major Depressive Disorder, Anxiety
Impact of Behavioral Activation on Depression and Quality of Life in Patients with Colon Cancer
The purpose of this randomized clinical trial is to study anxiety and depression symptoms at diagnosis in patients with colon cancer. Previous studies have shown that so-called.
- Conditions
- Depression - Major Depressive Disorder, Anxiety, Colon Cancer
- Trial name
- BAdepCa (NCT06745700)
- Testing
- Brief Behavioural Activation, Care as usual
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Region Västmanland
Colo-rectal Cancer
EMVI as a Determinant of Metastasis in Colorectal Cancer
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years.
- Trial name
- EVIDENCE (NCT06646341)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Neoplasms (Cancer / Tumors), Colorectal Neoplasms
A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment
Many clinical trials evaluating cancer treatments require patients to undergo testing for specific molecular markers as part of eligibility screening, typically using immunohistochemistry or sequencing.
- Conditions
- Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms
- Trial name
- FATHOM (NCT07814872)
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Harvard Medical School (HMS and HSDM)
Colorectal Cancer Screening, Lynch Syndrome
DYNAMICS-LYNCH：DNA Methylation Analysis in Stool for Screening of Lynch Syndrome-Associated Colorectal Cancer
Colorectal cancer (CRC) has high incidence and mortality rates globally. Over 1 million new cases are diagnosed annually, and about 600,000 people die from the disease each year.
- Trial name
- NCT06772844
- Testing
- fecal DNA methylation testing
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer (CRC)
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)
- Trial name
- NCT07106892
- Testing
- HLX43 Dose 1;, HLX43 Dose 2;, HLX43 Dose 3;
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Bowel Disease, Crohn Disease
Development of New Diagnostic Tools in Capsule Endoscopy
Patients participating to this study will provide images and videos of capsule endoscopy to train, tune and evaluate technological bricks of artificial intelligence solutions, in order to improve diagnostic performances of the…
- Conditions
- Bowel Disease, Crohn Disease, Celiac Disease, Chronic Diarrhea
- Trial name
- NOCE (NCT06152289)
- Where
- France
- Volunteers
- 10,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rectal Cancer
SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak
The goal of this clinical trial is to learn whether using a reinforcing material called SIS (small intestinal submucosa) during bowel connection after rectal cancer surgery can help prevent anastomotic leakage-a serious…
- Trial name
- NCT07209787
- Testing
- SIS-reinforced anastomosis
- Where
- China
- Volunteers
- 966 people
- Sponsor
- Beijing Chao Yang Hospital
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Rectal Neoplasms
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
This prospective observational study characterises the tumour immune microenvironment and microbial ecology of locally advanced rectal cancer before and during neoadjuvant therapy.
- Trial name
- NCT07920770
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University Union Hospital
Acute Lymphoblastic Leukemia
The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia
This study is a prospective longitudinal investigation. Data on disease-related information, gut microbiota composition, cancer-related symptoms, dietary intake, and levels of pro-inflammatory cytokines, LPS were collected…
- Trial name
- NCT07515430
- Testing
- Questionnaires set, fecal sample collecting
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Blood Cancer
Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving treatment for many malignant hematologic diseases.
- Trial name
- GUT-PREDICTION (NCT07305090)
- Testing
- Adult and pediatric patients with hematological diseases treated with allogeneic hematopoietic cell transplantation
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Urinary Catheters, Rectal Cancer
Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery
This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer.
- Conditions
- Urinary Catheters, Rectal Cancer, Urinary Retention
- Trial name
- NCT07346586
- Testing
- Tamsulosin group, 24-Hour Removal Group, 48-Hour Removal Group
- Where
- 2 sites in China
- Volunteers
- 1,545 people
- Sponsor
- The First Hospital of Jilin University
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Rectal Neoplasms
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer
The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the…
- Trial name
- COMREC (NCT05871762)
- Testing
- Registry study, no specific intervention
- Where
- China
- Volunteers
- 3,705 people
- Sponsor
- Peking Union Medical College Hospital